Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.